

[首页](#)[最新一期](#)[期刊动态](#)[过刊浏览](#)[医学视频](#)[在线投稿](#)[期刊检索](#)[期刊订阅](#)[合作科室](#)

期刊导读

8卷24期 2014年12月 [最新]



期刊存档

期刊存档

[查看目录](#)

期刊订阅



在线订阅



邮件订阅



RSS

作者中心



资质及晋升信息



作者查稿



写作技巧



投稿方式



作者指南

编委会

期刊服务



建议我们



会员服务



广告合作



继续教育

您的位置: [首页](#)>> 文章摘要[中文](#) [English](#)

树突状细胞肿瘤疫苗的研究及实践进展

袁媛, 苏川, 束永前

221009 江苏省, 徐州市中心医院肿瘤内科(袁媛); 南京医科大学病原生物学系(苏川); 南京医科大学第一附

束永前, Email: njshuyongqian@yeah.net

摘要: 癌症是威胁全球人民健康的头号杀手之一, 传统治疗手段(如手术、放疗、化疗)虽有进展仍不令人满意。发展新治疗策略仍迫在眉睫。由于树突状细胞疫苗为基础的免疫治疗能活化机体肿瘤相关抗原特异性杀灭肿瘤细胞, 而不伤及正常细胞, 目前已经成为肿瘤治疗的一个热点。

关键词: 树突细胞; 免疫疗法; 癌症疫苗

[评论](#) [收藏](#) [全](#)

文献标引: 袁媛, 苏川, 束永前. 树突状细胞肿瘤疫苗的研究及实践进展[J/CD]. 中华临床医师杂志: 电子版, 20

[复制](#)

参考文献:

[1] Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science, 2006, 313(5795): 1960-

[2] Kalinski P, Okada H. Polarized dendritic cells as cancer vaccines: directing dendritic cells to tumors[J]. Semin Immunol, 2010, 22(3): 173-182.

[3] Steinman RM. Decisions about dendritic cells: past, present, and future[J]. J Clin Invest, 2012, 30: 1-22.

[4] Barth RJ, Fisher DA, Wallace PK, et al. A randomized trial of ex vivo CD40L dendritic cell vaccine in colorectal cancer patients: tumor-specific immune response with improved survival[J]. Clin Cancer Res, 2010, 16(22): 5548-5556.

[5] Lesterhuis WJ, de Vries IJ, Schreiber G, et al. Route of administration modulates the efficacy of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients[J]. J Clin Oncol Res, 2011, 17(17): 5725-5735.

[6] Ma Y, Zhang Z, Tang L, et al. Cytokine-induced killer cells in the treatment of solid carcinomas: a systematic review and pooled analysis[J]. Cytotherapy, 2012, 14(

[7] Wang HL, Xu H, Lu WH, et al. In vitro and in vivo evaluations of human papillomavirus (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide as tumor vaccines for immunotherapy of cervical cancer[J]. Arch Gynecol Obstet, 2014

[8] Hong X, Dong T, Hu J, et al. Synergistical toll-like receptors activated dendritic cell antitumor effects against carcinoembryonic antigen-expressing colon cancer[J]. Int J Cancer, 2013, 28(1): 25-33.

[9] Kim HS, Park HM, Park JS, et al. Dendritic cell vaccine in addition to FOLFIRI increases antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer[J]. Vaccine, 2010, 28(49): 7787-7796.

[10] Chen L, Liang GP, Tang XD, et al. In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus[J]. Biochem Biophys Res Commun, 2005, 333(2): 934.

[11] Okada N, Iiyama S, Okada Y, et al. Immunological properties and vaccine effect of dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12[J]. J Clin Ther, 2005, 12(1): 72-83.

[12] Rahma OE, Ashtar E, Czystowska M, et al. A gynecologic oncology group phase II study of peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cell vaccine in recurrent recurrence risk ovarian cancer patients[J]. Cancer Immunol Immunother, 2012, 61(3): 311-320.

[13] Svane IM, Pedersen AE, Nikolajsen K, et al. Alterations in p53-specific T cell and CD8 lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2[J]. Vaccine, 2008, 26(36): 4716-4724.

[14] Chiappori AA, Soliman H, Janssen WE, et al. INGN-225: a dendritic cell-based vaccine (p53-DC) in small cell lung cancer: observed association between immune response and clinical chemotherapy effect[J]. Expert Opin on Biological Therapy, 2010, 10(6): 983-991.

[15] Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines[J]. Breast Cancer Research and Treatment, 2013, 138(1): 1-12.

[16] Ladjemi MZ, Jacot W, Chardès T, et al. Anti-HER2 vaccines: new prospects for immunotherapy[J]. Cancer Immunol Immunother, 2010, 59(9): 1295-1312.

[17] Kamigaki T, Kaneko T, Naitoh K, et al. Immunotherapy of autologous tumor by dendritic cell vaccines by a closed-flow electroporation system for solid tumors[J]. J Clin Invest, 2013, 123(7): 2971-2976.

[18] Dougan MG, Dranoff. Immune therapy for cancer[J]. Annu Rev Immunol, 2009, 27: 83-123.

[19] Hobo W, Strobbe L, Maas F, et al. Immunogenicity of dendritic cells pulsed with tumor antigen and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients[J]. J Clin Immunotherapy, 2013, 62(8): 1381-1392.

[20] Lauber K, Ernst A, Orth M, et al. Dying cell clearance and its impact on the efficacy of radiotherapy[J]. Front Oncol, 2012, 2: 116.

- [21] Frey B, Rubner Y, Kulzer L, et al. Antitumor immune responses induced by ionizing radiation and further immune stimulation[J]. *Cancer Immunol Immunother*, 2014, 63(1): 29–36.
- [22] Formenti SC, S Demaria. Combining radiotherapy and cancer immunotherapy: a paradigm shift. *Natl Cancer Inst*, 2013, 105(4): 256–265.
- [23] Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for its use[J]. *Nat Rev Clin Oncol*, 2010, 7(8): 455–465.
- [24] Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy[J]. *Nat Rev Clin Oncol*, 2004, 4(6): 423–436.
- [25] Borrello I, Sotomayor EM, Rattis FM, et al. Sustaining the graft-versus-tumor effect by posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor vaccines[J]. *Blood*, 2000, 95(10): 3011–3019.
- [26] Koike N, Pilon-Thomas S, Mule JJ. Nonmyeloablative chemotherapy followed by dendritic cell transfer and dendritic cell-based vaccination results in rejection of established melanoma[J]. *Immunother*, 2008, 31(4): 402–412.
- [27] Rettig L, Seidenberg S, Parvanova I, et al. Gemcitabine depletes regulatory T cells in mice and enhances triggering of vaccine-specific cytotoxic T-cells[J]. *Int J Cancer*, 2011, 129(4): 832–838.
- [28] Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy[J]. *Cancer Res*, 2005, 65(18): 8059–8064.
- [29] Chu CS, Boyer J, Schullery DS, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in complete remission[J]. *Cancer Immunol Immunother*, 2012, 61(5): 629–641.
- [30] Park YS, Bae JH, Son CH, et al. Cyclophosphamide potentiates the antitumor effect of dendritic cell immunization with injection of immature dendritic cells into irradiated tumor[J]. *Immunol Lett*, 2004, 40(4): 383–399.
- [31] Salem ML, Diaz-Montero CM, Al-Khami AA, et al. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)[J]. *Int J Cancer*, 2009, 182(4): 2030–2040.
- [32] Krishnadas DK, Shapiro T, Lucas K. Complete remission following decitabine/interferon- α vaccine for relapsed neuroblastoma[J]. *Pediatrics*, 2013, 131(1): 336–341.
- [33] Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction in cancer[J]. *Cancer Res*, 2004, 92: 13–27.
- [34] Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency[J]. *Cancer Res*, 2001, 23(2–3): 263–272.
- [35] Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor-induced development of dendritic cells and dramatically affects the differentiation of multiple dendritic cell lineages in vivo[J]. *Blood*, 1998, 92(11): 4150–4166.

- [36] Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial human tumors inhibits the functional maturation of dendritic cells[J]. *Nat Med*, 1996
- [37] Takahashi A, Kono K, Ichihara F, et al. Vascular endothelial growth factor of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokin *Immunol Immunother*, 2004, 53(6): 543-550.
- [38] Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial receptors 1 and 2 in dendritic cell differentiation[J]. *J Immunol*, 2005, 174(1): 215
- [39] Li B, Lalani AS, Harding TC, et al. Vascular endothelial growth factor bloc intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting can *Clin Cancer Res*, 2006, 12(22): 6808-6816.
- [40] Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation [J]. *Annu Rev Immunol*, 2006, 24: 99-146.
- [41] Rini BI, Weinberg V, Fong L, et al. Combination immunotherapy with prostatic pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serolog prostate cancer after definitive local therapy[J]. *Cancer*, 2006, 107(1): 67-74.
- [42] Kandalaft LE, Chiang CL, Tanyi J, et al. A Phase I vaccine trial using dend with autologous oxidized lysate for recurrent ovarian cancer[J]. *J Transl Med*, 2013,
- [43] Manzur S, Cohen S, Haimovich J, et al. Enhanced therapeutic effect of B cell CD20 antibodies upon combination with[J]. *Clinical & Experimental Immunology*, 2012,
- [44] Saha A, Chatterjee SK. Combination of CTL-associated antigen-4 blockade and regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse cancer[J]. *Scand J Immunol*, 2010, 71(2): 70-82.
- [45] Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity and PD-1 pathways[J]. *Immunol Rev*, 2008, 224: 166-182.
- [46] Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and *Rev Immunol*, 2008, 26: 677-704.
- [47] Fracol M, Xu S, Mick R, et al. Response to HER-2 pulsed DC1 vaccines is pre and estrogen receptor expression in DCIS[J]. *Ann Surg Oncol*, 2013, 20(10): 3233-3239
- [48] Ma J, Usui Y, Takeuchi M, et al. Human uveal melanoma cells inhibit the immune function of dendritic cells[J]. *Exp Eye Res*, 2010, 91(4): 491-499.
- [49] Escribano C, Delgado-Martin C, Rodriguez-Fernandez JL. CCR7-dependent stimulation in dendritic cells involves inhibition of GSK3beta[J]. *J Immunol*, 2009, 183(10): 628
- [50] Kim JH, Kang TH, Noh KH, et al. Enhancement of dendritic cell-based vaccine apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated *Immunol Lett*, 2009, 122(1): 58-67.
- [51] Kim JH, Kang TH, Noh KH, et al. Enhancement of DC vaccine potency by activation pathway with a small interfering RNA targeting PTEN[J]. *Immunology Letters*, 2010, 13

综 述

早产儿动脉导管未闭诊疗进展

钟桂朝, 李运泉, 王慧深. . 中华临床医师杂志: 电子版
2014;8(17):3175-3180.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

树突状细胞肿瘤疫苗的研究及实践进展

袁媛, 苏川, 束永前. . 中华临床医师杂志: 电子版
2014;8(17):3181-3185.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

| [编委会](#) | [联系我们](#) | [合作伙伴](#) | [友情链接](#) |

© 2014版权声明 中华临床医师杂志(电子版)编辑部
网站建设: 北京华夏世通信息技术有限公司 京ICP备0
北京市公安局西城分局备案编号: 110102000676